Poliwogg Regenerative Medicine Fund, Inc.
Poliwogg Regenerative Medicine Fund – Key Information
The Poliwogg Regenerative Medicine Fund, Inc. (the “Company”) is a ...
Poliwogg Regenerative Medicine Fund – Key Facts

Objective: Long-Term Capital Appreciation

Asset Class: Healthcare ...
Poliwogg Regenerative Medicine Fund – Additional Information

Distribution: The method of distribution being used by th...
Name
Title
Experience
Brock Reeve
President and Portfolio Manager
•
Executive Director, Harvard Stem Cell Institute ...
Our Population is Growing, Growing Older and Costing More
Source: U.S. Census Bureau
6
Aging Brings Many (Chronic) Diseases
Do you know anyone with:
Alzheimer’s Disease
Arthritis
Cancer
Diabetes
Heart Di...
Therapeutics & Devices 56%
Services 12%
Cell & Tissue Banks 13%
Tools & Reagents 19%
Regenerative Medicine
cancer
ca...
What Have We Begun to Learn in the Last Decade?

How to manipulate cells

Which tissues repair and how

Interacti...
Why Invest in Regenerative Medicine Now?

Technology is developing beyond research stage and is in the clinic/market
...
The Poliwogg Regenerative Medicine Fund provides individual investors access to innovative healthcare companies
•Ability ...
•
Small healthcare companies creating new products that address unmet medical needs
•
Healthcare venture capital outper...
Capital Markets Are Recognizing the Opportunity
Note: Market capitalization represents market value of 50 US-based regene...
The Market is Large and Growing
Source: Allied Market Research; Regenerative Medicine Market 2013-2020, June 2014. CAGR =...
Investment Sourcing: Private Companies
Academic Institutions
Pharmaceutical Companies
Corporate Venture
Venture Capita...
Firms: New Solutions, New Entrants
Lucentis: Novartis, Genentech (Roche)
Eylea: Bayer, Regeneron
New Entrants (private ...
Poliwogg Regenerative Medicine Fund – Key Facts

Objective: Long-Term Capital Appreciation

Asset Class: Healthcare ...
Disclaimer
These materials and any presentation of which they form a part are neither an offer to sell, nor a solicitatio...
Risk Factors
An investment in shares of our common stock involves a high degree of risk and may be considered speculative...
Contact Information
Company managed by:
Poliwogg Advisers, LLC
420 Lexington Avenue, Suite 920
New York, NY 10017
P (...
of 20

Poliwogg road-show-presentation

Poliwogg Regenerative Medicine Fund, Inc.
Published on: Mar 4, 2016
Published in: Investor Relations      
Source: www.slideshare.net


Transcripts - Poliwogg road-show-presentation

  • 1. Poliwogg Regenerative Medicine Fund, Inc.
  • 2. Poliwogg Regenerative Medicine Fund – Key Information The Poliwogg Regenerative Medicine Fund, Inc. (the “Company”) is a new business development company, that is intended to provide investors with access and exposure to both private and public companies in the fast growing regenerative medicine sector of healthcare. The Company seeks to: •Maximize long-term capital appreciation •Provide exposure to both public and private companies •Make investments in equity securities of growth companies engaged in regenerative medicine technologies •Pursue opportunities to invest in a range of technologies – tools, devices, cell therapies and drugs The Company is an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, as amended, and will be subject to reduced public company reporting requirements. The Company will elect to be regulated as a business development company, or BDC, and has no identifiable portfolio assets. There can be no assurance that the Company’s investment objective will be achieved or that the Company’s investment program will be successful. The Company is not intended as, and you should not construe it to be, a complete investment program. An investment in the Company involves a high degree of risk and should be considered speculative. You could lose some or all of your investment. For a summary of the risks associated with an investment in the Company, please see the back pages of this document and the “Risk Factors” section of the preliminary prospectus. The information in the Company’s preliminary prospectus and in this document is not complete and may be amended or changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This document is not an offer to sell these securities and is not a solicitation of an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Investors should consider the Company’s investment objective, risks and charges and expenses carefully before investing. The preliminary prospectus contains more complete information about the Company and should be read carefully before investing. A copy of the final prospectus, when available, can be obtained from WR Hambrecht + Co at (415) 551-8600 or Avondale Partners at (615) 467-3500. W.R. Hambrecht + Co., LLC and Avondale Partners, LLC are the underwriters for this offering. www.PoliwoggFunds.com 2
  • 3. Poliwogg Regenerative Medicine Fund – Key Facts  Objective: Long-Term Capital Appreciation  Asset Class: Healthcare  Ticker Symbol: PRMF1  Offering Price: $20.00 per share  Gross Selling Concession/Spread: 6%2  Base Management Fee: 1.75%2  Incentive Fee: 20%2  Hurdle Rate: 6%2  Expected Closing Date: December 2014  Minimum Fund Offering Size: $60 million3  Structure: Business Development Company  Investment Advisor: Poliwogg Advisers, LLC (“Poliwogg Advisers”) 3 1 Subject to official notice of issuance, the Company’s common stock has been approved for listing on The NASDAQ Capital Market under the symbol “PRMF”. 2 Please refer to “Fees and Expenses” section of the preliminary prospectus for information on the fees, charges and expenses associated with investing in the Company. 3 The Company’s shares of common stock are being offered on a best efforts basis, subject to a minimum requirement of $60 million in gross offering proceeds. The Company will not proceed with its initial public offering unless it satisfies all the applicable conditions for listing on The Nasdaq Capital Market and receives gross offering proceeds of at least $60 million. There can be no assurance that the Company will sell any or all of the shares to be sold pursuant to this offering. Investor funds will be deposited into an escrow account for the benefit of investors. The offering will not be completed unless the Company’s sell the minimum amount of shares to be sold, which are the shares the Company is offering. The escrow agent will not accept any investor funds until the date of the final prospectus. On the closing date, the escrow agent will notify the underwriters whether at least $60 million has been received, which is the amount necessary to purchase the minimum amount of shares to be sold in this offering.
  • 4. Poliwogg Regenerative Medicine Fund – Additional Information  Distribution: The method of distribution being used by the underwriters in this offering differs somewhat from that traditionally employed in underwritten offerings. The underwriters have agreed to use their “best efforts” to procure potential purchasers for the shares of common stock being. All investor funds received prior to closing will be deposited in an escrow account until closing. In the event the Company does not sell a minimum of 3,000,000 shares by the closing date in the final prospectus, escrowed funds will be promptly returned to investors without interest or deduction. In the event that the minimum of 3,000,000 shares are sold by such date, the Company will close on those funds received and promptly issue shares of common stock.  Investment: The Company is a newly organized business development company that invests primarily in the equity and equity-linked securities of companies involved in, or significantly benefitting from, stem cell science and other regenerative medical technologies, including companies involved in the development of drugs, devices or therapies generated, in whole or in part, from stem cell research or other regenerative medical technologies. The Company’s investment objective is to maximize long-term capital appreciation. In pursuing this objective, the Company seeks to realize capital appreciation from its equity and equity-linked investments. In light of this investment strategy, the Company does not anticipate that its portfolio will generate significant ordinary income from interest and dividends. As a result, investors should not expect regular distributions of ordinary income. As a new company with no investments, our initial public offering may be deemed to be a “blind pool” offering. An investor may not have the opportunity to evaluate historical data or assess investments prior to purchasing our shares.  Investment Adviser: Poliwogg Advisers is a wholly owned subsidiary of Poliwogg Holdings, Inc., a Delaware corporation. Poliwogg Advisers is newly registered as an investment adviser with the SEC under the Advisers Act. Poliwogg Advisers has no previous operating experience and has not previously managed a BDC or a RIC (“regulated investment company”).  Investment Advisory Fee: Poliwogg Advisers will be compensated for its services. Pursuant to the investment advisory agreement, Poliwogg Advisers will be entitled to a fee consisting of two components—a base management fee and an incentive fee. The base management fee will be calculated at an annual rate of 1.75% of the Company’s total assets which includes any borrowings for investment purposes and payable quarterly in arrears. The base management fee will be calculated based on the average of (1) the value of the Company’s total assets which includes any borrowings for investment purposes at the end of the current calendar quarter, and (2) the value of the Company’s total assets which includes any borrowings for investment purposes at the end of the preceding calendar quarter; and appropriately adjusted for any share issuances or repurchases, if any, during the current calendar quarter. Base management fees for any partial month or quarter will be pro-rated. The base management fee may or may not be taken in whole or in part at discretion of Poliwogg Advisers. The incentive fee is determined and payable in arrears as of the end of each calendar year (or upon termination of the investment advisory agreement, as of the termination date), beginning on the commencement of the Company’s operations, and will equal the lesser of (i) 20% of the Company’s realized capital gains during such calendar year, if any, calculated on an investment-by-investment basis, subject to a non-compounded preferred return, or “hurdle,” and a “catch-up” feature, and (ii) 20% of the Company’s realized capital gains, if any, on a cumulative basis from inception through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis, less the aggregate amount of any previously paid incentive fees. See “Investment Advisory Agreement and Administrative Services Agreement” in the preliminary prospectus for more information on the investment advisory fee. 4
  • 5. Name Title Experience Brock Reeve President and Portfolio Manager • Executive Director, Harvard Stem Cell Institute • Invested $15 - $20 million per year in regenerative medicine for over eight years • Formed strategic partnerships with biopharma, foundations and private equity investors • COO, Life Science Insights, an International Data Corporation company • Healthcare Consultant with IBM, Viant, SRI Sam Wertheimer, PhD Executive Vice President • Former Private Equity Partner at OrbiMed Advisors LLC • Director of the Office of Industrial Liaison at the NYU School of Medicine • Director of Technology Assessment at Paramount Capital, LLC • Registered Patent Agent at Darby & Darby • Research Scientist at Memorial Sloan Kettering Cancer Center Portfolio Managers 5
  • 6. Our Population is Growing, Growing Older and Costing More Source: U.S. Census Bureau 6
  • 7. Aging Brings Many (Chronic) Diseases Do you know anyone with: Alzheimer’s Disease Arthritis Cancer Diabetes Heart Disease Macular degeneration Muscle wasting Osteoporosis Parkinson’s Disease Stroke … not to mention injury… 7
  • 8. Therapeutics & Devices 56% Services 12% Cell & Tissue Banks 13% Tools & Reagents 19% Regenerative Medicine cancer cardiology dermatology neurology musculoskeletal Regenerative Medicine A New Path to Understanding and Curing Disease cell-based therapies immunotherapies gene therapies devices Top 5 Indications Source: Alliance for Regenerative Medicine, RM Annual Industry Report 2014 Multiple sectors for investment 8
  • 9. What Have We Begun to Learn in the Last Decade?  How to manipulate cells  Which tissues repair and how  Interaction between a cell and its environment  How to create “disease in a dish”  How to impact a complex disease like cancer  How to build organs  New ways to impact conditions such as obesity, aging 9
  • 10. Why Invest in Regenerative Medicine Now?  Technology is developing beyond research stage and is in the clinic/market  Investors can leverage public sector investments  UK – Cell Therapy Catapult, UK Stem Cell Bank  US Army – AFIRM – Armed Forces Institute of Regenerative Medicine  Biopharma industry is engaged  Disease Foundations heavily involved  ALS Association; SMA Foundation; JDRF- Juvenile Diabetes Research Foundation International  Public and private investment opportunities  ~700 companies currently in the field  25% of biotech IPOs in the second half of last year were regenerative medicine companies Note: The above referenced entities are not affiliated with the Company. 10
  • 11. The Poliwogg Regenerative Medicine Fund provides individual investors access to innovative healthcare companies •Ability to invest in both emerging private companies as well as, to an extent, existing public companies •Ability to invest in regenerative medicine companies that may: •Address the fundamental causes of disease and injury that affect us all •Change the economics of drug discovery and clinical trials •Understand how to replace the ability to repair and regenerate that we lose over time Investment Opportunity 11
  • 12. • Small healthcare companies creating new products that address unmet medical needs • Healthcare venture capital outperformed other venture sectors in the decade from 2000 to 20101,2 1 Forbes 2013. Debunking Myths about Biotech Venture Captial 2 Booth BL, Salehizadeh B. In defense of life sciences venture investing. Nature Biotechnology 29, 579–583 (2011) Investment Opportunity Source: Update on Healthcare Venture Capital, Fairview Capital Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. The past performance shown above is not representative of the performance of the Company. 12
  • 13. Capital Markets Are Recognizing the Opportunity Note: Market capitalization represents market value of 50 US-based regenerative medicine companies 13
  • 14. The Market is Large and Growing Source: Allied Market Research; Regenerative Medicine Market 2013-2020, June 2014. CAGR = Compounded Annual Growth Rate, which represents year-over-year growth rate over a specified period of time Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. The past performance shown above is not representative of the performance of the Company. 14
  • 15. Investment Sourcing: Private Companies Academic Institutions Pharmaceutical Companies Corporate Venture Venture Capital / Private Equity Portfolio Managers have relationships with leading scientists, institutions and corporations across the field of regenerative medicine Brock Reeve, President, Poliwogg Regenerative Medicine Fund Investment Sourcing Opportunity Note: The above referenced entities are not affiliated with the Company. 15
  • 16. Firms: New Solutions, New Entrants Lucentis: Novartis, Genentech (Roche) Eylea: Bayer, Regeneron New Entrants (private and public): Advanced Cell Technology, Applied Genetic Technologies, Avalanche Biotechnologies, Genable Technologies, GenSight Biologics, jCyte, Iconic, NightstaRX, Regenerative Patch Technology, ReNeuron, Spark Therapeutics, Stem Cells Inc. Using cells, scaffolds, and gene therapy to attack eye disease caused by age, injury and genetics Case Study: Age Related Macular Degeneration Increasingly, innovation is coming from new entrants into a market, not incumbents New Entrant Note: The above referenced entities are not affiliated with the Company. 16
  • 17. Poliwogg Regenerative Medicine Fund – Key Facts  Objective: Long-Term Capital Appreciation  Asset Class: Healthcare  Ticker Symbol: PRMF1  Offering Price: $20.00 per share  Gross Selling Concession/Spread: 6%2  Base Management Fee: 1.75%2  Incentive Fee: 20%2  Hurdle Rate: 6%2  Expected Closing Date: December 2014  Minimum Fund Offering Size: $60 million3  Structure: Business Development Company  Investment Advisor: Poliwogg Advisers, LLC (“Poliwogg Advisers”) 17 1 Subject to official notice of issuance, the Company’s common stock has been approved for listing on The NASDAQ Capital Market under the symbol “PRMF”. 2 Please refer to “Fees and Expenses” section of the preliminary prospectus for information on the fees, charges and expenses associated with investing in the Company. 3 The Company’s shares of common stock are being offered on a best efforts basis, subject to a minimum requirement of $60 million in gross offering proceeds. The Company will not proceed with its initial public offering unless it satisfies all the applicable conditions for listing on The Nasdaq Capital Market and receives gross offering proceeds of at least $60 million. There can be no assurance that the Company will sell any or all of the shares to be sold pursuant to this offering. Investor funds will be deposited into an escrow account for the benefit of investors. The offering will not be completed unless the Company’s sell the minimum amount of shares to be sold, which are the shares the Company is offering. The escrow agent will not accept any investor funds until the date of the final prospectus. On the closing date, the escrow agent will notify the underwriters whether at least $60 million has been received, which is the amount necessary to purchase the minimum amount of shares to be sold in this offering.
  • 18. Disclaimer These materials and any presentation of which they form a part are neither an offer to sell, nor a solicitation of an offer to purchase, an interest in Poliwogg Regenerative Medicine Fund, Inc. (the “Company”, “our”, and “we”). These materials are being provided for discussion purposes only with regard to a proposed capital raising transaction by the Company. It should be noted that there is no guarantee that the proposed capital raising transaction will occur. Investors are advised to carefully consider the investment objective, risks and charges and expenses of the Company before investing. The preliminary prospectus, which has been filed with the Securities and Exchange Commission (the “SEC”), contains this and other information about the Company and should be read carefully before investing. The proposed capital raising transaction may be made only by means of a prospectus, copies of which may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov or from W. R. Hambrecht & Co., LLC, 909 Montgomery Street, Suite 3, San Francisco, CA 94133, ATT: Prospectus Group. The information herein and in the preliminary prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold until the registration statement filed with the SEC is effective. These materials are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted or would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. You or your clients may lose money by investing in the Company. The Company is not intended to be a complete investment program and, due to the uncertainty inherent in all investments, there can be no assurance that the Company will achieve its investment objectives. These materials and any presentation of which they form a part contain statements that, to the extent they are not recitations of historical fact, constitute “forward-looking statements.” Actual outcomes and results could differ materially from those forecasts due to the impact of many factors beyond the control of the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The words “believe” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “aim,” “forecast,” “project,” “will,” “may,” “might,” “should,” “could” and similar expressions (or their negative) identify certain of these forward-looking statements. Forward-looking statements include statements regarding the regenerative medicine industry and markets; strategies, outlook and growth prospects; future plans; distribution plans; and regulatory actions. These forward-looking statements are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical trends and other data available from third parties. These assumptions are inherently subject to significant risks, uncertainties and contingencies that are difficult or impossible to predict and are beyond the Company’s control, and the Company may not achieve or accomplish these expectations, beliefs or projections. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. There is no guarantee that any of the estimates, targets or projections illustrated in these materials and any presentation of which they form a part will be achieved. Such information has been provided for illustrative purposes only. It should not be assumed that any particular investment will be profitable. We do not undertake to update any forward-looking statements except as otherwise required by law. The information contained herein is not intended to provide, and should not be relied upon for, accounting, legal or tax advice or investment recommendations. Such information is qualified in its entirety by reference to the more detailed discussions contained in the Company’s preliminary prospectus. Prospective investors should also seek advice from their own independent tax, accounting, financial, investment and legal advisors to properly assess the merits and risks associated with an investment in the Company in light of their own financial condition and other circumstances. An investment in the Company is speculative and involves a high degree of risk. There can be no guarantee that the Company’s investment objective will be achieved. The Company may engage in other investment practices that may increase the risk of investment loss. An investor could lose all or substantially all of his or her investment. The Company’s fees and expenses may be considered high and, as a result, such fees and expenses may offset the Company’s profits. For a summary of certain of these and other risks, please see “Risk Factors” herein and in the preliminary prospectus. 18
  • 19. Risk Factors An investment in shares of our common stock involves a high degree of risk and may be considered speculative. You should carefully consider the information found in “Risk Factors” in the preliminary prospectus before deciding to invest in shares of our common stock. The following are some of the risks an investment in us involves: •Prior to this offering, there has been no public market for our common stock and we cannot assure you that the market price of shares of our common stock will not decline following this offering. •Our common stock may trade below its net asset value per share, which limits our ability to raise additional equity capital. •Investing in our common stock may involve an above average degree of risk. •The market price of our common stock may fluctuate significantly. •We will face significant competition for investment opportunities, which could delay deployment of our capital, reduce returns and result in losses. •We are a new company and have no operating history. •As a new company with no investments, our initial public offering may be deemed to be a “blind pool” offering. An investor may not have the opportunity to evaluate historical data or assess investments prior to purchasing our shares. •If we are unable to raise substantial funds in our “best efforts” initial public offering in excess of our minimum amount, we will be limited in the number and type of investments we may make, and the value of your investment in us may be reduced in the event our assets underperform. •We may be unable to invest a significant portion of the net proceeds of our offering on acceptable terms in an acceptable timeframe. •In light of our investment strategy, we do not anticipate that the portfolio will generate significant ordinary income from interest and dividends. As a result, investors should not expect regular distributions of ordinary income from the Company. •A stockholder’s interest in us will be diluted if we issue additional shares, which could reduce the overall value of an investment in us. •Our stockholders will experience dilution in their ownership percentage unless they opt into our dividend reinvestment plan. •Our investments in prospective portfolio companies may be risky, and we could lose all or part of our investment. •Our portfolio companies may have limited operating histories and financial resources. •Our investment strategy includes investing in equity securities of early-stage, emerging growth companies, which involve a degree of risk that can result in substantial losses as these companies are in a “start-up” stage of development with little or no operating history, often operate at a loss and may have no marketable or approved products or technology. •Our investment strategy includes investing in equity securities in venture-stage companies, which are subject to many risks, including dependence on the need to raise additional capital, volatility, intense competition, shortened product life cycles, dependence on key management, changes in regulatory and governmental programs and periodic downturns and you could lose all or part of your investment. Additionally, these investments will not yield returns until a liquidity event occurs and there can be no assurance that an IPO or sale or joint venture will occur for these companies. •We may invest in micro-cap companies and companies we may hope will have successful initial public offerings. •We may invest in companies that do not have venture capital or private equity firms as equity investors, and these companies may entail a higher risk of loss than do companies with institutional equity investors, which could increase the risk of loss of your investment. •Investing in regenerative medicine companies involves a number of significant risks, any one of which could have a material adverse effect on our operating results, including the following: •An investment strategy that includes investments in privately held regenerative medicine companies presents certain challenges, including the lack of available information about these companies. These investments may involve a high degree of business and financial risk, and they are generally illiquid. •An investment strategy that includes investments in privately-held or publicly-traded, micro-cap regenerative medicine companies may involve greater risks than investing in larger, more established issuers. •Our investments in regenerative medicine companies are focused on the biotechnology, life sciences and drug discovery industries, which are subject to many risks, including risks associated with product development, volatility, intense competition, shortened product life cycles, regulatory requirements and periodic downturns. Such investments subject us to the risk of significant loss if any of these industry sectors experiences a downturn. 19
  • 20. Contact Information Company managed by: Poliwogg Advisers, LLC 420 Lexington Avenue, Suite 920 New York, NY 10017 P (855) 753-6484 e info@poliwoggfunds.com For additional information: WR Hambrecht + CO 909 Montgomery Street, Suite 3 San Francisco, CA 94133 P (415) 551-8600 e info@wrhambrecht.com Additional offices: 1 East 52 Street, 3rd Floor New York, NY, 10022 Avondale Partners 3102 West End Ave., Suite 1100 Nashville, TN 37203 P (615) 467-3500 e info@avondalepartnersllc.com 20

Related Documents